Short-term efficacy of anifrolumab in the treatment of patients with systemic lupus erythematosus

Bugrova O.: Orenburg State Medical University, Orenburg, Russia

Zonova E.V.: Novosibirsk State Medical University. Municipal Clinical Policlinic №1, Municipal Center of Clinical Immunology, Novosibirsk

Novikov P.: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia

Pugach V.A.: Sechenov University, Moscow, Russia

Churilova V.O.: Municipal Clinical Policlinic №1, Municipal Center of Clinical Immunology, Novosibirsk. Novosibirsk State Medical University

Bulanov N.: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia

Moiseev S.: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia

Download in PDF

Summary

Anifrolumab is a fully human monoclonal antibody that targets the type I IFN-α receptor subunit and blocks the action of the type I IFN.

Aim

To evulate the efficacy and safety profile of anifrolumab in a case series of patients with systemic lupus erythematosus (SLE).

Results

The most common manifestations of active disease (median SLEDAI-2K score 10.5) were mucocutaneous, musculoskeletal, and immunologic. Median SLEDAI-2K score decreased from 10.5 to 6.0 at 3 months in 10 patients and from 12.0 to 4.0 at 6 months in 8 patients. At 3 months, the SRI (4) response rate was 80%. SRI (4) response was sustained in all 8 patients who were followed for 6 months. Lupus low disease activity state was achieved at 3 months in 30% (3/10) of patients and at 6 months in 63% (5/8). There were no SLE relapses during treatment with anifrolumab. The glucocorticoid dose was 5 mg or lower in 5 of 10 patients at 3 months and in 4 of 8 patients at 6 months. There were no adverse events requiring discontinuation anifrolumab.

Conclusion

In our case series of patients with active SLE who did not respond to standard immunosuppressive treatment, anifrolumab rapidly reduced disease activity and provided steroid sparing effect.

Key words

Systemic lupus erythematosus, treatment, anifrolumab.